Arquitos Capital Management commentary for the second quarter ended June 30, 2024.
Dear Partner:
Arquitos returned 3.5% net of fees in the second quarter of 2024, bringing the year-to-date return to 23.5%.
We were up nearly 40% on the year at the end of May, but had a down June due to the continued delays with Liquidia coming to market with their PAH and PH-ILD inhaler, Yutrepia. I continue to be optimistic that we will get a resolution in the near term. However, we did get good news during the quarter as the judge in one of...
Membership Required
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe and get an extra 30% off annual with code Summer30This article is only available for Premium Members
Subscribe today and get :
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually
Don’t have an account?
Subscribe and get an extra 30% off annual with code Summer30Already a member? Log in here